Prospective, case-control study of serological response after two doses of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in transfusion-dependent thalassemic patients

Prospective, case-control study of serological response after two doses of BNT162b2 anti-SARS-CoV-2 mRNA vaccine in transfusion-dependent thalassemic patients

Saved in:

Bibliographic Details
Main Authors:	NICOLA SGHERZA, Stefania Zucano, Angelantonio Vitucci, Antonio Palma, Francesco Tarantini, Daniela Campanale, Luigi Vimercati, Angela Maria Vittoria Larocca, Domenico Visceglie, Amalia Acquafredda, Angelo Ostuni, Daniela Di Gennaro, Carmen Vitucci, Silvio Tafuri, Pellegrino Musto
Format:	Article
Language:	English
Published:	PAGEPress Publications 2022-06-01
Series:	Mediterranean Journal of Hematology and Infectious Diseases
Online Access:	https://www.mjhid.org/index.php/mjhid/article/view/4990
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

“Hemolysis, or not Hemolysis, that is the question”. Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency.
by: NICOLA SGHERZA, et al.
Published: (2020-10-01)

Proteomic and serologic assessments of responses to mRNA-1273 and BNT162b2 vaccines in human recipient sera
by: Thomas E. Hickey, et al.
Published: (2025-01-01)

Humoral immune response after anti-SARS-CoV-2 vaccine “booster” dose in patients with monoclonal gammopathy of undetermined significance (MGUS)
by: NICOLA SGHERZA, et al.
Published: (2023-01-01)

Antibody response to breakthrough SARS-CoV-2 infection in “booster” vaccinated patients with multiple myeloma according to B/T/NK lymphocyte absolute counts and anti-CD38 treatments
by: NICOLA SGHERZA, et al.
Published: (2024-02-01)

Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19
by: Dogan Mustafa, et al.
Published: (2023-06-01)

BNT162b2 COVID-19 Vaccine Induced Immune Thrombocytopenic Purpura
by: A. K. Ghosh, et al.
Published: (2022-01-01)

Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan
by: Mitsuhiro Nagano, et al.
Published: (2024-12-01)

Improving BNT162b2 mRNA vaccine tolerability without efficacy loss by Pidotimod supplementation
by: Claudio Ucciferri, et al.
Published: (2022-02-01)

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine
by: Kayvon Modjarrad, et al.
Published: (2024-11-01)

EFFECTS OF DARATUMUMAB ON HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA WHO ARE PLANNED TO RECEIVE AUTOLOGOUS TRANSPLANTATION: WHAT’S THE RELEVANCE?
by: Pellegrino Musto, et al.
Published: (2024-08-01)

Delirium as an Adverse Reaction to BNT162b2 mRNA Vaccine from Pfizer Inc., and BioNTech
by: Lilia M. Sierra Galan, et al.
Published: (2025-01-01)

Long-term immunity after BNT162b2 mRNA COVID-19 vaccination in pediatric patients with cancer
by: K.L. Juliëtte Schmidt, et al.
Published: (2024-12-01)

Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescentsResearch in context
by: Qiong Wu, et al.
Published: (2025-01-01)

BNT162b2 versus mRNA-1273 mRNA COVID-19 vaccines as the third booster for the patients with underlying cancer
by: Amnuay Kleebayoon, et al.
Published: (2023-12-01)

Cellular and humoral response to SARS-CoV-2 vaccine BNT162b2 in adults with Chronic Kidney Disease G4/5.
by: Anja Rosdahl, et al.
Published: (2024-12-01)

High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents
by: Marloes I Hofstee, et al.
Published: (2025-01-01)

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
by: Catherine Riou, et al.
Published: (2024-01-01)

Case report: Development of anxiety symptoms after receiving the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine: a case series
by: Maris Taube, et al.
Published: (2025-01-01)

The Antioxidant Effect of Erythropoietin on Thalassemic Blood Cells
by: Johnny Amer, et al.
Published: (2010-01-01)

Anti-SARS-Cov-2 S-RBD IgG Formed after BNT162b2 Vaccination Can Bind C1q and Activate Complement
by: Anas H. A. Abu-Humaidan, et al.
Published: (2022-01-01)

Distinct response patterns of endothelial markers to the BNT162b2 mRNA COVID-19 booster vaccine are associated with the spike-specific IgG antibody production
by: Beatriz Castro-Robles, et al.
Published: (2025-01-01)

Iron Overload in Transfusion-Dependent Indonesian Thalassemic Patients
by: Pandji Irani Fianza, et al.
Published: (2021-01-01)

BNT162b2 Vaccination during Pregnancy Protects Both the Mother and Infant: Anti-SARS-CoV-2 S Antibodies Persistently Positive in an Infant at 6 Months of Age
by: Chetna Mangat, et al.
Published: (2021-01-01)

Transient Pneumonitis as a Possible Adverse Reaction to the BNT162b2 COVID-19 mRNA Vaccine in a Patient with Rheumatoid Arthritis: A Case Report and Review of the Literature
by: Yusuke Ohkubo, et al.
Published: (2022-01-01)

Thalassemic DNA-Containing Red Blood Cells Are under Oxidative Stress
by: Mutaz Dana, et al.
Published: (2012-01-01)

Total body irradiation-based myeloablative conditioning for acute lymphoblastic leukaemia patients undergoing allogeneic haematopoietic stem cell transplantation: the best way to prevent relapse in a real-world scenario
by: Mario Delia, et al.
Published: (2025-01-01)

Epidemiological Characteristics and Family Relatives among Thalassemic Patients in Sulaimani City, Kurdistan Region, Iraq
by: Kamal Jalal Rashid
Published: (2018-07-01)

Effectiveness of the BNT162b2 XBB.1.5-adapted vaccine against COVID-19 hospitalization related to the JN.1 variant in Europe: a test-negative case-control study using the id.DRIVE platformResearch in context
by: Jennifer L. Nguyen, et al.
Published: (2025-01-01)

Factors Affecting the Transmission Hepatitis C Among the Thalassemic Patients in Al-Najaf Al-Ashraf governorate
by: Hassan Musa Abd, et al.
Published: (2022-06-01)

Study of Frequency and Characteristics of Red Blood Cell Alloimmunization in Thalassemic Patients: Multicenter Study from Palestine
by: Adham Abu Taha, et al.
Published: (2019-01-01)

Aged Garlic Extract (AGE) and Its Constituent S-Allyl-Cysteine (SAC) Inhibit the Expression of Pro-Inflammatory Genes Induced in Bronchial Epithelial IB3-1 Cells by Exposure to the SARS-CoV-2 Spike Protein and the BNT162b2 Vaccine
by: Jessica Gasparello, et al.
Published: (2024-12-01)

Unveiling the molecular and comorbidity profile among transfusion-dependent and nontransfusion-dependent beta-thalassemic patients in Baghdad city
by: Atyab Abdulhameed Alaqidi, et al.
Published: (2024-12-01)

Seroprevalence of Hepatitis C, Hepatitis B, Cytomegalovirus, and Human Immunodeficiency Viruses in Multitransfused Thalassemic Children in Upper Egypt
by: Ramadan A. Mahmoud, et al.
Published: (2016-01-01)

Prevalence and clinical profile of hepatitis C virus infections in multitransfused thalassemic patients in the capital twin cities of Pakistan
by: Z. Z. Piracha, et al.
Published: (2025-01-01)

Mm-Wave Building Penetration Losses: A Measurement-Based Critical Analysis
by: Silvi Kodra, et al.
Published: (2024-01-01)

Interfacial‐Polarization Engineering in BNT‐Based Bulk Ceramics for Ultrahigh Energy‐Storage Density
by: Wenjun Cao, et al.
Published: (2024-12-01)

Prevalence of dental caries, oral health status, malocclusion status, and dental treatment needs in thalassemic children: A cross-sectional study
by: Ankit Mahajan, et al.
Published: (2024-11-01)

Aliovalent Sm-doping enables BNT-based realxor ferroelectric ceramics with > 90% energy efficiency
by: Dong-Xu Li, et al.
Published: (2024-12-01)

Editorial: Inorganic chemistry, polymer chemistry, and solid state chemistry editor’s pick 2024
by: Luís D. Carlos, et al.
Published: (2025-01-01)

Analytical Characterization of a Transmission Loss of an Antenna-Embedded Wall
by: Lauri Vaha-Savo, et al.
Published: (2024-01-01)